1. Home
  2. MC vs TVTX Comparison

MC vs TVTX Comparison

Compare MC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$57.70

Market Cap

5.1B

Sector

Finance

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

SELL

Current Price

$61.41

Market Cap

5.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MC
TVTX
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.3B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
MC
TVTX
Price
$57.70
$61.41
Analyst Decision
Buy
Strong Buy
Analyst Count
8
13
Target Price
★ $72.88
$40.62
AVG Volume (30 Days)
678.8K
★ 1.4M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
★ 3.88%
N/A
EPS Growth
N/A
★ 92.89
EPS
★ 0.75
N/A
Revenue
N/A
N/A
Revenue This Year
$18.28
$44.76
Revenue Next Year
$17.22
$35.51
P/E Ratio
$78.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.06
$22.59
52 Week High
$78.22
$68.73

Technical Indicators

Market Signals
Indicator
MC
TVTX
Relative Strength Index (RSI) 32.59 45.50
Support Level $51.06 $53.76
Resistance Level $70.99 $67.49
Average True Range (ATR) 2.15 2.56
MACD -0.46 -0.73
Stochastic Oscillator 9.75 30.55

Price Performance

Historical Comparison
MC
TVTX

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: